您当前所在的位置:首页 > 产品中心 > 产品信息
Sodium orthovanadate_分子结构_CAS_13721-39-6)
点击图片或这里关闭

Sodium orthovanadate

产品号 S2000 公司名称 Selleck Chemicals
CAS号 13721-39-6 公司网站 http://www.selleckchem.com
分子式 Na3O4V 电 话 (877) 796-6397
分子量 183.90841 传 真 (832) 582-8590
纯 度 电子邮件 sales@selleckchem.com
保 存 -20°C Chembase数据库ID: 72834

产品价格信息

请登录

产品别名

标题
Sodium orthovanadate
IUPAC标准名
3-oxo-3-(sodiooxy)-2,4-dioxa-3-vanada-1,5-disodapentane
IUPAC传统名
3-oxo-3-(sodiooxy)-2,4-dioxa-3-vanada-1,5-disodapentane

产品登记号

CAS号 13721-39-6

产品性质

成盐信息 Sodium Salt
保存条件 -20°C

产品详细信息

详细说明 (English)
Research Area
Description Cancer
Biological Activity
Description Sodium orthovanadate is an alkaline phosphatase and (Na,K)-ATPase inhibitor with IC50 of 10 μM.
Targets Phosphatase (Na,K)-ATPase
IC50 10 μM [1] 40 nM [2]
In Vitro In transient forebrain ischemia, Sodium orthovanadate rescues cells from delayed neuronal death in the hippocampal CA1 region. The neuroprotective effects of Sodium orthovanadate and IGF-1 are associated with preventing decreased Akt-Ser-473 phosphorylation in the CA1 region observed immediately after reperfusion. Akt is moderately activated in the cell bodies and dendrites of pyramidal neurons after orthovanadate treatment. The Sodium orthovanadate treatment also prevents the decrease in phosphorylation of mitogen-activated protein kinase (MAPK). [3] Sodium orthovanadate inhibits ASK1 through the PI3-K/Akt-dependent pathway. [4] Sodium orthovanadate up-regulates Akt activity in the brain and in turn rescue neurons from delayed neuronal death by inhibiting FKHR-dependent or -independent death signals in neurons. [4]
In Vivo In a rat model of myocardial ischemic infarction, sodium orthovanadate rescues cells from ischemia/reperfusion injuries. Post-treatment with Sodium orthovanadate reduces infarct size in a dose-dependent manner. [5] Sodium orthovanadate treatment also ameliorates contractile dysfunction of the left ventricle 72 hours after reperfusion. The cytoprotective action of Sodium orthovanadate treatment is closely associated with inhibition of fodrin breakdown. Sodium orthovanadate treatment inhibits caspase-3 activation induced by ischemia. [6]
Clinical Trials
Features
Protocol
Kinase Assay [2]
ATPase assay The coupled assay linking ADP production to NADH oxidation is used for all ATPase assays. The fraction of active enzyme is determined by measuring enzyme activity after linearity has been achieved by the activity prior to addition of Sodium orthovanadate. Final steady state hydrolysis rates are independent of the order addition of Sodium orthovanadate and enzyme.
Animal Study [6]
Animal Models Male Sprague-Dawley rats
Formulation 0.9% saline
Doses 0.005 mL/min/100g of b.wt. over 20 minutes
Administration Administered via i.v.
References
[1] Wu Y, et al. Acta Pharmacol Sin, 2005, 26(3), 345-352.
[2] Cantley LC Jr, et al. J Biol Chem, 1977, 252(21), 7421-7423.
[3] Kawano T, et al. J Cereb Blood Flow Metab, 2001, 21(11), 1268-1280.
[4] Wu DN, et al. Neurosci Lett, 2006, 404(1-2), 98-102.
[5] Fukunaga K, et al. J Pharmacol Sci, 2005, 98(3), 205-211.
[6] Takada Y, et al. J Pharmacol Exp Ther, 2004, 311(3), 1249-1255.